Search research articles
Contact Us
Filters
Showing results (521-530 of 580) with videos related to
Page
of 58
Sort By:
Cancer Discovery
|
December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha, Nektaria M Leli, Angelique Onorati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
Douglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Frontiers in Oncology
|
August 28, 2020
ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer
Van T Hoang, Margarite D Matossian, Deniz A Ucar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop
Kristen L Mueller, Marc R Theoret, Steven J Lemery, et al.
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
JCI Insight
|
February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
EMBO Molecular Medicine
|
April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Ileabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Page
of 58
Search research articles
Search
Showing results (521-530 of 580) with videos related to
Sort By:
Page
of 58
Cancer Discovery
|
December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha, Nektaria M Leli, Angelique Onorati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
Douglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Frontiers in Oncology
|
August 28, 2020
ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer
Van T Hoang, Margarite D Matossian, Deniz A Ucar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop
Kristen L Mueller, Marc R Theoret, Steven J Lemery, et al.
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
JCI Insight
|
February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
EMBO Molecular Medicine
|
April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Ileabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Page
of 58